Jump to main content
Jump to site search

Issue 8, 2015
Previous Article Next Article

Enzyme responsive mesoporous silica nanoparticles for targeted tumor therapy in vitro and in vivo

Author affiliations

Abstract

This study reports a biocompatible controlled drug release system based on mesoporous silica nanoparticles (MSNs) for tumor microenvironment responsive drug delivery. It was fabricated by grafting phenylboronic acid conjugated human serum albumin (PBA-HSA) onto the surfaces of MSNs as a sealing agent, via an intermediate linker of a functional polypeptide, which was composed of two functional units: the polycation cell penetrating peptide (CPP) polyarginine, and matrix metalloproteinase 2 (MMP-2) substrate peptide. A series of characterizations confirmed that the system had been successfully constructed. In vitro tests proved that the anticancer drug loading system could efficiently induce cell apoptosis in vitro. More importantly, the in vivo tumor experiments confirmed that the anticancer loading system could efficiently inhibit tumor growth with minimal side effects.

Graphical abstract: Enzyme responsive mesoporous silica nanoparticles for targeted tumor therapy in vitro and in vivo

Back to tab navigation

Supplementary files

Publication details

The article was received on 06 Jan 2015, accepted on 07 Jan 2015 and first published on 08 Jan 2015


Article type: Paper
DOI: 10.1039/C5NR00072F
Nanoscale, 2015,7, 3614-3626

  •   Request permissions

    Enzyme responsive mesoporous silica nanoparticles for targeted tumor therapy in vitro and in vivo

    J. Liu, B. Zhang, Z. Luo, X. Ding, J. Li, L. Dai, J. Zhou, X. Zhao, J. Ye and K. Cai, Nanoscale, 2015, 7, 3614
    DOI: 10.1039/C5NR00072F

Search articles by author

Spotlight

Advertisements